Head to head
Takeda Pharmaceutical vs Teva Pharmaceutical Industries
Side-by-side on the measures that matter, with a plain-English read. Full detail: TAK · TEVA
TAK
Takeda Pharmaceutical
21.77+1.68%
1-year price shape — +57% over the period
Quant Rating C · 90/100
vs
TEVA
Teva Pharmaceutical Industries
39.23+1.79%
1-year price shape — +62% over the period
Quant Rating C · 91/100
1-year performance, rebased to 100
Teva Pharmaceutical Industries edges it on the scoreable measures. Teva Pharmaceutical Industries has the highest Quant Rating (91); Teva Pharmaceutical Industries has done best over the past year (+62%); Teva Pharmaceutical Industries trades cheapest on trailing earnings.
| TAK | TEVA | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 21.77 | 39.23 |
| Change today | +1.68% | +1.79% |
| 1-year return | +57.5% | +61.6% |
| Market cap | $69.76B | $45.77B |
| 52-week range | 13.92 – 22.07 | 24.34 – 44.57 |
| Valuation | ||
| P/E (TTM) | 311.00 | 91.23 |
| P/E percentile, own 5-yr range | 100th | 99th |
| P/B | 1.50 | 5.74 |
| Dividend yield | 1.44% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.30 | 1.21 |
| Net profit (TTM) | $-970.94M | $1.41B |
| Revenue (TTM) | $4.69T | $17.23B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +6.7% | -1.9% |
| Gross margin | 65.8% | 53.5% |
| Operating margin | 14.3% | 19.2% |
| Net margin | 0.9% | 2.9% |
| Free cash flow (TTM) | $433.95B | $1.23B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 51.3% | 79.4% |
| Insider activity (12mo) | 19 buy / 31 sell | 23 buy / 24 sell |
| Short interest (% of float) | 0.1% | 2.4% |
| Analyst consensus | 100% buy (1) | 100% buy (13) |
| Analyst price target | $50 (+132%) | $52 (+31%) |
| StockVane view | ||
| StockVane Quant Rating | C (90) | C (91) |
| Company | ||
| Employees | 47,029 | 33,950 |
| Founded | 1781 | 1901 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.